Back to top
more

PerkinElmer, Inc. (PKI)

(Delayed Data from NYSE)

$96.59 USD

96.59
692,880

+1.71 (1.80%)

Updated May 3, 2019 04:03 PM ET

After-Market: $96.59 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Can Diagnostic Revenues Drive PerkinElmer (PKI) Q3 Earnings?

PerkinElmer (PKI) likely to gain from strong segmental revenues in Q3; a raised earnings guidance for 2018 is promising.

Why Is PerkinElmer (PKI) Up 7% Since Last Earnings Report?

PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    PerkinElmer (PKI) Q2 Earnings & Revenues Top, EPS View Up

    Solid performance by PerkinElmer's (PKI) DAS and Diagnostics arms is a key positive in Q2. The company saw strength across all major geographies in Asia, Americas, Europe and the BRIC nations.

      PerkinElmer (PKI) Tops Q2 Earnings and Revenue Estimates

      PerkinElmer (PKI) delivered earnings and revenue surprises of 5.81% and 1.38%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

        Should You Buy PerkinElmer (PKI) Ahead of Earnings?

        PerkinElmer (PKI) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

          Can Solid European Sales Boost Inogen (INGN) in Q2 Earnings?

          Strong performance in Europe is likely to boost Inogen's (INGN) top line in Q2. However, decline rental-revenues is a concern.

            What's in Store for Pacific Biosciences' (PACB) Q2 Earnings?

            Pacific Biosciences' (PACB) flagship Sequel System is likely to drive Q2 results; competition is a headwind.

              Can Kidney Care Business Drive DaVita's (DVA) Q2 Earnings?

              DaVita's (DVA) flagship Kidney Care business likely to drive Q2 results; solid international presence encourages.

                Can R&D Focus Drive DENTSPLY SIRONA's (XRAY) Q2 Earnings?

                DENTSPLY SIRONA's (XRAY) continued focus on research and development and strategic buyouts are likely to drive Q2 results.

                  What's in Store for Cerner (CERN) This Earnings Season?

                  Cerner's (CERN) Q2 results are likely to show softer performance owing to declining revenues across core business segments.

                    What's in Store for AmerisourceBergen (ABC) in Q3 Earnings?

                    AmerisourceBergen's (ABC) Q3 results are likely to be driven by its core Pharmaceutical Distribution business; a competitive industry is a headwind.

                      Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?

                      Becton, Dickinson's (BDX) core BD Medical likely to register solid results in Q3; a possible decline in BD Life Sciences raises concern.

                        Can Business Services Aid athenahealth's (ATHN) Q2 Earnings?

                        athenahealth's (ATHN) core Business Services unit is likely to drive growth in Q2; the company's focus on cloud-based services is encouraging.

                          Can Diagnostic Revenues Drive PerkinElmer (PKI) Q2 Earnings?

                          Strong performance in the Diagnostics Segment is likely to drive PerkinElmer's (PKI) Q2 results. The segment fortifies the company's market position in terms of exclusiveness of services.

                            Zacks Industry Outlook Highlights: Waters, Mettler-Toledo and PerkinElmer

                            Zacks Industry Outlook Highlights: Waters, Mettler-Toledo and PerkinElmer

                              Aniruddha Ganguly headshot

                              Instruments - Scientific Outlook: Growth Prospects Abound

                              Instruments - Scientific industry's growth prospect is quite bright in the near term given rising spending by the government and academic labs.

                                Here's Why You Should Invest in PerkinElmer (PKI) Stock Now

                                PerkinElmer (PKI) gains from stellar Q1 performance; a raised guidance holds promise.

                                  PerkinElmer (PKI) Q1 Earnings & Revenues Top, '18 View Up

                                  Solid prospects in PerkinElmer's (PKI) DAS segment are the key drivers of Q1. Strength in life sciences end markets, informatics profile and OneSource have given the top line a boost.

                                    Is a Surprise Coming for PerkinElmer (PKI) This Earnings Season?

                                    PerkinElmer (PKI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.

                                      Can Diagnostic Revenues Drive PerkinElmer (PKI) Q1 Earnings?

                                      PerkinElmer (PKI) gains from EUROIMMUN buyout, solid guidance buoys optimism.

                                        DENTSPLY to Acquire OraMetrix, Boost CAD-CAM Dental Unit

                                        The acquisition of OraMetrix is likely to bolster DENTSPLY's (XRAY) dental business.

                                          Here's Why You Should Invest in athenaheath Stock Right Now

                                          athenahealth's (ATHN) strong product portfolio is likely to expand its customer base in the coming quarters.

                                            Luminex (LMNX) Product Portfolio Solid, Competition Rife

                                            Luminex's (LMNX) flagship VERIGENE and ARIES systems are likely to boost its growth trajectory.

                                              3 Reasons Why You Should Invest in Fresenius Medical Now

                                              Wide range of dialysis products, deliberate initiatives to gain market traction and solid international foothold are major catalysts for Fresenius Medical (FMS) at the moment.

                                                Favorable Market Trend & Core Business Expansion Aid STERIS

                                                STERIS' (STE) string of six buyouts in fiscal 2018 keeps us upbeat about the stock. The same is expected to strengthen its Healthcare Specialty Services and Applied Sterilization Technologies arms.